Litcius/Paper detail

Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial

Frank Cools, Saverio Virdone, J.P.S. Sawhney, Renato D. Lópes, Barry Jacobson, Juan I. Arcelus, Richard Hobbs, Harry Gibbs, Jelle C L Himmelreich, Peter MacCallum, Sebastian Schellong, Sylvia Haas, Alexander G.G. Turpie, Walter Ageno, Ana Thereza Rocha, Gloria Kayani, Karen S. Pieper, Ajay K. Kakkar, Ajit Avhad, Murillo de Oliveira Antunes, Ana Thereza Rocha, Jesus Gonzales Lama, Atul Abyankar, Adrian Kormann, Louis van Zyl, Upendra Kaul, Frances Adams, Ivan Aloysius, Matthew Capehorn, Pradeep Kumar, Rajesh Mahajan

2022The Lancet Haematology61 citationsDOIOpen Access PDF

Topics & Concepts

MedicineLow molecular weight heparinPopulationClinical endpointRandomized controlled trialAdverse effectInternal medicineClinical trialSurgeryPediatricsHeparinEnvironmental healthHeparin-Induced Thrombocytopenia and ThrombosisIntramuscular injections and effectsCOVID-19 Clinical Research Studies
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial | Litcius